Summit Therapeutics Inc. Common Stock (SMMT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.99 (+5.67%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Summit Therapeutics Inc. Common Stock (SMMT)
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Key Insights

Critical company metrics and information
  • Share Price

    $18.54
  • Market Cap

    $13.67 Billion
  • Total Outstanding Shares

    737.45 Million Shares
  • Total Employees

    105
  • Dividend

    No dividend
  • IPO Date

    March 5, 2015
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.smmttx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$411.09 Million
Net Cash Flow From Financing Activities$411.09 Million
Net Cash Flow From Investing Activities, Continuing$-228.25 Million
Net Cash Flow$69.94 Million
Net Cash Flow From Investing Activities$-228.25 Million
Net Cash Flow From Operating Activities, Continuing$-112.89 Million
Net Cash Flow, Continuing$69.94 Million
Net Cash Flow From Operating Activities$-112.89 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$-196.68 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$196.97 Million
Income/Loss From Continuing Operations Before Tax$-196.68 Million
Operating Expenses$196.88 Million
Net Income/Loss$-196.68 Million
Revenues$287000.00
Nonoperating Income/Loss$85000.00
Income/Loss From Continuing Operations After Tax$-196.68 Million
Basic Average Shares$739.45 Million
Diluted Average Shares$739.45 Million
Net Income/Loss Available To Common Stockholders, Basic$-196.68 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Earnings Per Share$0.23
Operating Income/Loss$-196.59 Million
Diluted Earnings Per Share$0.23
Costs And Expenses$196.88 Million
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Liabilities$47.80 Million
Noncurrent Liabilities$5.92 Million
Other Non-current Assets$12.30 Million
Assets$502.85 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity$437.92 Million
Accounts Payable$3.25 Million
Noncurrent Assets$12.56 Million
Liabilities And Equity$502.85 Million
Liabilities$64.93 Million
Fixed Assets$265000.00
Wages$7.96 Million
Current Assets$490.29 Million
Equity Attributable To Parent$437.92 Million
Current Liabilities$59.01 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.